Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial - PubMed (original) (raw)
Clinical Trial
. 2000 May 8;160(9):1294-300.
doi: 10.1001/archinte.160.9.1294.
Affiliations
- PMID: 10809032
- DOI: 10.1001/archinte.160.9.1294
Clinical Trial
Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial
E N Vergis et al. Arch Intern Med. 2000.
Abstract
Objective: To compare the efficacy and safety of azithromycin dihydrate monotherapy with those of a combination of cefuroxime axetil plus erythromycin as empirical therapy for community-acquired pneumonia in hospitalized patients.
Methods: Patients were enrolled in a prospective, randomized, multicenter study. The standard therapy of cefuroxime plus erythromycin was consistent with the American Thoracic Society, Canadian Community-Acquired Pneumonia Consensus Group, and Infectious Disease Society of America consensus guidelines. The doses were intravenous azithromycin (500 mg once daily) followed by oral azithromycin (500 mg once daily), intravenous cefuroxime (750 mg every 8 hours), followed by oral cefuroxime axetil (500 mg twice daily), and erythromycin (500-1000 mg) intravenously or orally every 6 hours. Randomization was stratified by severity of illness and age. Patients who were immunosuppressed or residing in nursing homes were excluded.
Results: Data from 145 patients (67 received azithromycin and 78 received cefuroxime plus erythromycin) were evaluable. Streptococcus pneumoniae and Haemophilus influenzae were isolated in 19% (28/145) and 13% (19/145), respectively. The atypical pathogens accounted for 33% (48/145) of the etiologic diagnoses; Legionella pneumophila, Chlamydia pneumoniae, and Mycoplasma pneumoniae were identified in 14% (20/ 145), 10% (15/145), and 9% (13/145), respectively. Clinical cure was achieved in 91% (61/67) of the patients in the azithromycin group and 91% (71/78) in the cefuroxime plus erythromycin group. Adverse events (intravenous catheter site reactions, gastrointestinal tract disturbances) were significantly more common in patients who received cefuroxime plus erythromycin (49% [30/78]) than in patients who received azithromycin (12% [8/67]) (P<.001).
Conclusions: Treatment with azithromycin was as effective as cefuroxime plus erythromycin in the empirical management of community-acquired pneumonia in immunocompetent patients who were hospitalized. Azithromycin was well tolerated.
Similar articles
- A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. File TM Jr, et al. Antimicrob Agents Chemother. 1997 Sep;41(9):1965-72. doi: 10.1128/AAC.41.9.1965. Antimicrob Agents Chemother. 1997. PMID: 9303395 Free PMC article. Clinical Trial. - Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.
Plouffe J, Schwartz DB, Kolokathis A, Sherman BW, Arnow PM, Gezon JA, Suh B, Anzuetto A, Greenberg RN, Niederman M, Paladino JA, Ramirez JA, Inverso J, Knirsch CA. Plouffe J, et al. Antimicrob Agents Chemother. 2000 Jul;44(7):1796-802. doi: 10.1128/AAC.44.7.1796-1802.2000. Antimicrob Agents Chemother. 2000. PMID: 10858333 Free PMC article. Clinical Trial. - Cefuroxime axetil: an updated review of its use in the management of bacterial infections.
Scott LJ, Ormrod D, Goa KL. Scott LJ, et al. Drugs. 2001;61(10):1455-500. doi: 10.2165/00003495-200161100-00008. Drugs. 2001. PMID: 11558834 Review. - Clinical use of cefuroxime in paediatric community-acquired pneumonia.
Olivier C. Olivier C. Paediatr Drugs. 2000 Sep-Oct;2(5):331-43. doi: 10.2165/00128072-200002050-00001. Paediatr Drugs. 2000. PMID: 11022795 Review.
Cited by
- Atypical pneumonia (Review).
Georgakopoulou VE, Lempesis IG, Tarantinos K, Sklapani P, Trakas N, Spandidos DA. Georgakopoulou VE, et al. Exp Ther Med. 2024 Sep 11;28(5):424. doi: 10.3892/etm.2024.12713. eCollection 2024 Nov. Exp Ther Med. 2024. PMID: 39301259 Free PMC article. Review. - Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.
Liu Y, Zhang Y, Zhao W, Liu X, Hu F, Dong B. Liu Y, et al. Front Pharmacol. 2019 Oct 31;10:1237. doi: 10.3389/fphar.2019.01237. eCollection 2019. Front Pharmacol. 2019. PMID: 31736751 Free PMC article. Review. - Hypervirulent Klebsiella pneumoniae.
Russo TA, Marr CM. Russo TA, et al. Clin Microbiol Rev. 2019 May 15;32(3):e00001-19. doi: 10.1128/CMR.00001-19. Print 2019 Jun 19. Clin Microbiol Rev. 2019. PMID: 31092506 Free PMC article. Review. - Medication Use for Childhood Pneumonia at a Children's Hospital in Shanghai, China: Analysis of Pattern Mining Algorithms.
Tang C, Sun H, Xiong Y, Yang J, Vitale C, Ruan L, Ai A, Yu G, Ma J, Bates D. Tang C, et al. JMIR Med Inform. 2019 Mar 22;7(1):e12577. doi: 10.2196/12577. JMIR Med Inform. 2019. PMID: 30900998 Free PMC article. - Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective.
Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J, Menzella F, Blasi F, Aliberti S, Restrepo MI; GLIMP Study Group. Gramegna A, et al. BMC Infect Dis. 2018 Dec 18;18(1):677. doi: 10.1186/s12879-018-3565-z. BMC Infect Dis. 2018. PMID: 30563504 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical